Your browser doesn't support javascript.
loading
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Koch, Marcus W; Moral, Ester; Brieva, Luis; Mostert, Jop; Strijbis, Eva Mm; Comtois, Jacynthe; Repovic, Pavle; Bowen, James D; Wolinsky, Jerry S; Lublin, Fred D; Cutter, Gary.
Afiliación
  • Koch MW; Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Moral E; Department of Neurology, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain.
  • Brieva L; Neuroimmunology Group, Department of Medicine, University of Lleida-IRBLleida, Lleida, Spain Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Mostert J; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
  • Strijbis EM; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Comtois J; Department of Medicine, Neurology Service, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.
  • Repovic P; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.
  • Bowen JD; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.
  • Wolinsky JS; Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
  • Lublin FD; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cutter G; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Mult Scler ; 29(14): 1776-1785, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37830451
BACKGROUND: Clinical relapses are the defining feature of relapsing forms of multiple sclerosis (MS), but relatively little is known about the time course of relapse recovery. OBJECTIVE: The aim of this study was to investigate the time course of and patient factors associated with the speed and success of relapse recovery in people with relapsing-remitting MS (RRMS). METHODS: Using data from CombiRx, a large RRMS trial (clinicaltrials.gov identifier NCT00211887), we measured the time to recovery from the first on-trial relapse. We used Kaplan-Meier survival analyses and Cox regression models to investigate the association of patient factors with the time to unconfirmed and confirmed relapse recovery. RESULTS: CombiRx included 1008 participants. We investigated 240 relapses. Median time to relapse recovery was 111 days. Most recovery events took place within 1 year of relapse onset: 202 of 240 (84%) individuals recovered during follow-up, 161 of 202 (80%) by 180 days, and 189 of 202 (94%) by 365 days. Relapse severity was the only factor associated with relapse recovery. CONCLUSION: Recovery from relapses takes place up to approximately 1 year after the event. Relapse severity, but no other patient factors, was associated with the speed of relapse recovery. Our findings inform clinical practice and trial design in RRMS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá